Abstract
In this study, we compared three domains of social cognition (emotion processing, mentalization, and attribution bias) to clinical and computational language measures in 63 participants with schizophrenia spectrum disorders. Based on the active inference model for discourse, we hypothesized that emotion processing and mentalization, but not attribution bias, would be related to language disturbances. Clinical ratings for speech disturbance assessed disorganized and underproductive dimensions. Computational features included speech graph metrics, use of modal verbs, use of first-person pronouns, cosine similarity of adjacent utterances, and measures of sentiment; these were represented by four principal components characterizing content-rich speech, insular speech, local coherence, and affirmative speech. We found that higher clinical ratings for disorganized speech predicted greater impairments in both emotion processing and mentalization, and that these relationships remained significant when accounting for demographic variables, overall psychosis symptoms, and verbal ability. Similarly, computational features reflecting insular speech also consistently predicted greater impairment in emotion processing. There were notable trends for underproductive speech and decreased content-rich speech predicting mentalization ability. Exploratory longitudinal analyses in a small subset of participants (n=17) found that improvements in both emotion processing and mentalization were predicted by improvements in disorganized speech. Attribution bias did not demonstrate strong relationships with language measures. Altogether, our findings are consistent with the active inference model of discourse and suggest greater emphasis on treatments that target social cognitive and language systems.
Competing Interest Statement
Dr. Tang is a paid scientific advisor for Winterlight Labs, Inc., and receives research funding from them. Dr. Tang is also a co-founder of North Shore Therapeutics and holds equity to this company. Dr. Malhotra is a consultant for Genomind, Inc., InformedDNA, Janssen Pharmaceuticals and Acadia Pharmaceuticals. Dr. Kane is a consultant for or receives honorarium from Alkermes, Allergan, Dainippon Sumitomo, H. Lundbeck, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Novartis Pharmaceuticals, Otsuka, Reviva, Roche, Saladex, Sunovion, Takeda, and Teva. He receives grant support from Otsuka, Lundbeck, Sunovion, and Janssen. He is a shareholder of Vanguard Research Group, LB Pharmaceuticals, and North Shore Therapeutics. Dr. Kane receives royalties from UptoDate. The other authors have no financial conflicts of interest.
Funding Statement
This project was supported by the Brain and Behavior Research Foundation Young Investigator Award (SXT) and the American Society of Clinical Psychopharmacology Early Career Research Award (SXT). Data for a portion of the participants (n=29) was collected in partnership with, and with financial support from, Winterlight Labs, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the Feinstein Institutes for Medical Research gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
[stang3{at}northwell.edu, ycong{at}northwell.edu, anikzad{at}northwell.edu, amehta8{at}northwell.edu, sberretta{at}northwell.edu, jkane2{at}northwell.edu, amalhotra{at}northwell.edu]
csunghye{at}ldc.upenn.edu
katrin.hansel{at}yale.edu
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
